drugset / Trial / NCT00003760
Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Phase 2
Completed
3 enrolled
The University of Texas Health Science Center at San Antonio
Merck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collabUniversity of Texas · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage III or stage IV pancreatic cancer that cannot be surgically removed.
Timeline
- Start
- 1998-11
- Primary completion
- 2000-05
- Completion
- 2000-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | irofulven | Small molecule | — | Intravenous |